Which Therapy for Acute Heart Attacks? (The WEST Study)

This study has been completed.
Sponsor:
Collaborators:
Hoffmann-La Roche
Sanofi
Eli Lilly and Company
Information provided by:
University of Alberta
ClinicalTrials.gov Identifier:
NCT00121446
First received: July 13, 2005
Last updated: January 19, 2006
Last verified: July 2005

July 13, 2005
January 19, 2006
July 2003
Not Provided
  • composite of 6 elements defined by: death
  • recurrent myocardial infarction
  • heart failure
  • cardiogenic shock
  • refractory ischemia
  • major ventricular arrhythmia
Same as current
Complete list of historical versions of study NCT00121446 on ClinicalTrials.gov Archive Site
  • 90 and 180 minute ECG ST resolution
  • QRS determined infarct size at discharge/day 7
  • CK infarct size determined by area under the curve or peak CK-MB
Same as current
Not Provided
Not Provided
 
Which Therapy for Acute Heart Attacks? (The WEST Study)
Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study

In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty.

WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.

The principal objective of WEST is to compare the impact on clinical outcomes of the following three treatment groups defined as Group A: optimal pharmacologic therapy (prompt administration of tenecteplase (TNKase) and enoxaparin) at the earliest point of medical contact with usual post MI care; Group B: an identical pharmacological reperfusion strategy followed by an early invasive strategy including timely mechanical intervention, Group C: timely primary percutaneous coronary intervention (PCI), undertaken after enoxaparin and an oral loading dose of clopidogrel.

The secondary objective of WEST is to compare clinical outcomes of patients receiving optimal pharmacologic therapy and a strategy of usual post-MI care, Group A versus protocol-mandated early catheterisation and PCI, Group B.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Myocardial Infarction
  • Drug: tenecteplase
  • Drug: enoxaparin
  • Drug: clopidogrel
  • Procedure: percutaneous coronary intervention
Not Provided
Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Armstrong PW. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J. 2011 Feb;161(2):283-90. doi: 10.1016/j.ahj.2010.10.033.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
Not Provided
Not Provided

Inclusion Criteria:

  • Male or non-pregnant female patients aged >18 years
  • Patients with symptoms presumed secondary to STEMI lasting at least 20 minutes and accompanied by ECG evidence >2 mm of ST elevation in 2 or more contiguous precordial leads or in 2 or more limb leads;or > 1mm ST elevation in 2 or more limb leads coupled with >1 mm ST depression in 2 or more contiguous precordial leads such that the total ST deviation is >4 mm; or presumed new left bundle branch block
  • Earliest point of care and randomisation must be within 6 hours of onset of symptoms as defined in previous criteria
  • Females of child-bearing age, not using a generally accepted method of contraception must have a negative urine pregnancy test
  • Written informed consent prior to randomisation of study

Exclusion Criteria:

  • PCI expected to commence within < 60 minutes from identification of suitable candidate
  • Inability to have angiography/PCI within 3 hrs from randomisation
  • Active bleeding or known hemorrhagic diathesis
  • Any history of stroke, transient ischemic attack, dementia or structural CNS damage e.g. neoplasm, aneurysm, AV malformation
  • Major surgery or trauma within the past 3 months
  • Previous Coronary Artery Bypass Graft (CABG)
  • Use of abciximab (ReoPro) or other GP IIb/IIIa antagonists within the preceding 7 days
  • Any minor head trauma and/or any other trauma occurring after onset of the current myocardial infarction
  • Significant hypertension (i.e. SBP > 180 mm HG and/or DBP > 110mm HG) at any time from presentation (earliest point of care) to randomisation
  • Current treatment with vitamin K antagonist (warfarin) resulting with an INR > 1.5
  • Anticipated difficulty obtaining vascular access
  • Prolonged (>10 min) cardiopulmonary resuscitation or cardiogenic shock
  • Patients who have participated in an investigational drug study within 7 days prior to randomisation
  • Known renal insufficiency (prior creatinine >2.5 mg% for men and >2.0 mg% for women)
  • Treatment with standard unfractionated heparin (heparin sodium) >5000 IU or a therapeutic dose of any low molecular weight heparin, within 6 hours prior to randomisation
  • Known thrombocytopenia (prior platelet count below 100 000/ul)
  • Known sensitivity to TNKase, clopidogrel, heparin, low molecular weight heparin or abciximab
  • Pregnancy or lactation, parturition within the previous 30 days
  • Any serious concomitant systemic or life limiting disorder that would be incompatible with the trial
  • Inability to follow protocol and comply with follow-up requirements
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00121446
CVC1002
Not Provided
Not Provided
University of Alberta
  • Hoffmann-La Roche
  • Sanofi
  • Eli Lilly and Company
Study Chair: Paul W. Armstrong, M.D. Canadian VIGOUR Centre
University of Alberta
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP